The Journal is Indexed in
6 - Additional rosiglitazone therapy to other oral antidiabetic combinations or insulin therapy provides metabolic control in patients with type 2 diabetes
Sema Uçak, Okcan Basat, Selçuk Şeber, Akın Kürklü, Çiğdem Yazıcı Ersoy, Yüksel Altuntaş
Objective: This study tries to evaluate the efficacy of use of rosiglitazone in combination with other oral antidiabetic agents (at least two) or insulin treatment.
Study Design: This was a single centre, randomized, controlled, open, prospective trial. A total number of 90 type 2 diabetic patients, 37-82 years old were eligible for the study if they had HbAlc values over 7%, C-Peptide level greater than
0. 6 nmol/L, BMl between 20-40 at screening. Exclusion criteria were patients with angina or cardiac insufficiency, renal impairment, hepatic disease. Patients has already been treated with OADs (group 1, n=40) or insulin (group2, n=50) twice daily and had similar age and BMl, and a poor metabolic control (HbAl c>7%) under at least 3 months of therapy. A rosiglitazone maleate 4mg/day therapy was added to their previous therapies. All patients were followed up for 24 weeks.
Results: In group 1, additional rosiglitazone therapy reduced HbAlc from baseline by 1.63 percentage points (p=0.000) af¬ter 24weeks. In group 2, additional rosiglitazone therapy reduced HbAlc from baseline by 0.83 percentage points (p=0.000) after 24weeks.
Conclusion: Our study showed that rosiglitazone treatment is both effective in combination OAD or insulin treated patients with type 2 diabetes who have poor metabolic control.
Keywords: Rosiglitazone, type 2 diabetes mellitus.
To read full article click